Processa Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Supplemental Cash Flow Information

Supplemental Cash Flow Information

3 Months Ended

Sep. 30, 2013

Supplemental Cash Flow Information

10. SUPPLEMENTAL CASH FLOW INFORMATION:

	Nine Months ended September 30,		For the period from March 29, 2011 (date of inception) through September 30,
	2013	2012	2013
Cash paid for interest	$ 95,042	$ 154,070	$ 438,277
Cash paid for income taxes	$ 100	$ 100	$ 300
Series C Dividend payable in accounts payable	$ 27,068	$ --	$ 27,068
Series D Dividend payable in accrued expenses	$ 24,407	$ --	$ 24,407

Non-Cash investing and financing transactions
Repayment of senior secured notes payable with issuance of Series D preferred shares	$ 749,982	$ --	$ 749,982